Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
Onuzo
Obed C
OC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006330:Heart Defects, Congenital / Q000175:diagnosis* / Q000821:virology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D012016:Reference Values; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D012136:Respiratory Syncytial Viruses / Q000187:drug effects*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab